Morgan Stanley Maintains Equal-Weight on Globus Medical, Raises Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri maintains an Equal-Weight rating on Globus Medical (NYSE:GMED) and raises the price target from $67 to $71.
July 15, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Drew Ranieri maintains an Equal-Weight rating on Globus Medical and raises the price target from $67 to $71.
The raised price target from $67 to $71 by a reputable analyst at Morgan Stanley is a positive signal for investors, indicating potential upside. However, the Equal-Weight rating suggests a neutral stance on the stock's performance relative to the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100